LAB Standard BioTools
- 2.480
- +0.040+1.64%
- 2.500
- +0.020+0.81%
Standard BioTools News
Sector Update: Health Care Stocks Decline Late Afternoon
Health care stocks retreated late Thursday afternoon, with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB) dro
Sector Update: Health Care
Health care stocks were falling late Thursday afternoon, with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund (XLV) shedding 0.6%. The iShares Biotechnology ETF (IBB)
Standard BioTools: Workforce Cut and Management Reshuffle Post-Merger
Standard BioTools Expects To Achieve $45M-$50M In Annualized Operating Expense Savings In Fiscal 2025
Standard BioTools Expects To Achieve $45M-$50M In Annualized Operating Expense Savings In Fiscal 2025
Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth
Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025Management to discuss first quarter 2024 financial results, restructuring and strategic initiatives on May 8, 2024
Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ("Standard BioTools" or the "Company") (Nasdaq: LAB) today announced that it will report first quarter 2024 fin
One Standard BioTools Insider Raised Their Stake In The Previous Year
From what we can see, insiders were net buyers in Standard BioTools Inc.'s (NASDAQ:LAB ) during the past 12 months. That is, insiders acquired the stock in greater numbers than they sold it.
Standard BioTools Initiated at Buy by TD Cowen
Standard BioTools Initiated at Buy by TD Cowen
Standard BioTools (LAB.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $3.50.
Standard BioTools (LAB.US) was first covered by TD Cowen, which gave it a buy rating, with a target price of $3.50.
TD Cowen Initiates Coverage On Standard BioTools With Buy Rating, Announces Price Target of $3.5
TD Cowen analyst Daniel Brennan initiates coverage on Standard BioTools (NASDAQ:LAB) with a Buy rating and announces Price Target of $3.5.
Standard BioTools Inc. (NASDAQ:LAB) Surges 6.7%; Individual Investors Who Own 35% Shares Profited Along With Institutions
Key Insights The considerable ownership by individual investors in Standard BioTools indicates that they collectively have a greater say in management and business strategy 51% of the business is he
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging
PDF Version New advancements, including automation, aim to fast-forward spatial biologySOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), drive
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday
Health care stocks were leaning higher pre-bell Thursday, with the Health Care Select Sector SPDR Fund (XLV) unchanged and the iShares Biotechnology ETF (IBB) up 0.4%. MacroGenics (MGNX) said interim
Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC) and Standard BioTools (LAB)
Jefferies Initiates Coverage On Standard BioTools With Buy Rating, Announces Price Target of $3.25
Jefferies analyst Matthew Stanton initiates coverage on Standard BioTools (NASDAQ:LAB) with a Buy rating and announces Price Target of $3.25.
Standard BioTools Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/04/2024 19.49% Jefferies → $3.25 Initiates Coverage On → Buy 07/12/2023 47.06% Keybanc → $4 Initiates C
Standard BioTools Enters Into Multi-Year Medicine Research Engagement With Bristol-Myers Squibb
Standard BioTools (LAB) said late Wednesday it agreed to enter into a multi-year strategic engagement with Bristol-Myers Squibb (BMY) for the use of the SomaScan platform for translational medical res
Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research
PDF Version SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human
When Should You Buy Standard BioTools Inc. (NASDAQ:LAB)?
While Standard BioTools Inc. (NASDAQ:LAB) might not have the largest market cap around , it saw a significant share price rise of 39% in the past couple of months on the NASDAQGS. The recent ral
Standard BioTools Streamlines Structure and Strengthens Governance
Analysis
Price Target
No Data
